openPR Logo
Press release

2019 - 2025 Glioblastoma Multiforme Treatment Market | GBM Market

02-22-2019 10:56 AM CET | Health & Medicine

Press release from: Precision Business Insights

Glioblastoma Multiforme Treatment Market

Glioblastoma Multiforme Treatment Market

Global Glioblastoma Multiforme Treatment Market, Its Market Trends And Analysis

Glioblastoma multiforme is the high-grade glioma and potent malignant brain tumor that affects glial cells. Glioblastoma multiforme contains the complexly differentiated neoplastic astrocytes which are the subtype of central nervous system. Glioblastoma multiforme is different from the anaplastic astrocytoma due to the presence of hyperplastic blood vessels and necrotic tissue.

Request Sample Report:

The global glioblastoma multiforme treatment market is growing at a significant rate due to increase in the geriatric population, and changes in the lifestyle. The increase in alcohol consumption, a rise in malaria prevalence, and the increase in the incidence of seizures are the key factors driving the global glioblastoma multiforme treatment market. In addition to that, increased R & D in gene therapy, molecular biotechnology for the treatment of CNS associated disorders, urgent need of alternative treatment procedures due to the resistance of glioma cells to conventional therapies are anticipated to boost the glioblastoma treatment market.

However, major restraints of the glioblastoma multiforme disease market are current treatment therapies such as radiation and chemotherapy does not prevent tumor recurrence that causes death in glioblastoma multiforme patients. Similarly, high expenditure for the genomics-based research, less number of drugs available in the market, and the high cost of treatment are expected to hinder the glioblastoma multiforme treatment market growth.

The global Glioblastoma multiforme treatment market is divided into following categories-
1. Drug type
• Temozolomide
• Bevacozumab
• carmustine
• Radiosensitizers
• Others
2. End-users
Hospital, retail and online pharmacies
And lastly on the basis of geographical regions, the glioblastoma treatment market segmented into following regions- North America, Asia-Pacific, Europe, the Middle East & Africa, and Latin America. North America dominates the glioblastoma multiforme disease market followed by Europe and Asia-Pacific. North America region growth is attributed to increase in the prevalence of glioblastoma multiforme disease, investments in R &D, and increasing CNS cancers in aging population. Company’s betting heavily on research activities due to lack of drugs to treat glioblastoma multiforme in the market.

Similarly, National Brain Tumor Society, Brain Tumor Foundation of Canada, and American Brain Tumor Association are the health organizations engaged in raising awareness about glioblastoma multiforme leading to the growth of glioblastoma multiforme treatment market. Europe glioblastoma multiforme disease market revenue growth is driven by increase in geriatric population, change in lifestyle and increase in research and development activities by various pharmaceutical companies. Asia-Pacific is expected to be the fastest growing market due to improved healthcare infrastructure, and rising awareness of glioblastoma multiforme treatment.

Some of the key players in global glioblastoma multiforme treatment market are Merck & Co Inc. (U.S.), Teva Pharmaceutical Industries, Ltd. (Israel), Arbor Pharmaceuticals LLC. (U.S.), Sun Pharmaceutical Industries, Ltd. (India), Celldex Therapeutics, Inc. (U.S.), Bristol-Myers Squibb Co. (U.S.), AstraZeneca (U.K.), GlaxoSmithKline plc. (U.K.), Apogenix (Germany), Pfizer, Inc. (U.S.), and Vascular Biogenics (Israel) to name a few. In 2015, CANbridge Life Sciences acquired license for to develop, manufacture and commercialize Apogenix’s APG101 onco-immunotherapy in glioblastoma for China.

Increase in prevalence of brain tumors driving the growth of glioblastoma multiforme treatment market. Moreover, various drugs which are under clinical trials are expected to fuel the growth of glioblastoma multiforme treatment market. Rising product approvals from USFDA also expected to drive revenue of glioblastoma treatment market. For e.g. in 2005, USFDA approved Temozolomide (Temodar) capsules, developed by Schering Corporation (Merck & Co., Inc.) to treat newly diagnosed patients with glioblastoma multiforme disease associated with radiotherapy and then as maintenance treatment. Similarly, entry of generics into the market also increases the growth of glioblastoma multiforme treatment market.

For More Information :

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customized market research services based on our client needs.

Kemp House,
152 – 160 City Road,
London EC1V 2NX
Toll Free (US): +1-866-598-1553
Website @

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release 2019 - 2025 Glioblastoma Multiforme Treatment Market | GBM Market here

News-ID: 1609747 • Views: 698

More Releases from Precision Business Insights

Interventional Radiology Market Growth, Industry Outlook And Opportunities 2022
Precision Business Insights published a research report on “Global Interventional Radiology Market: By Product Type (Ultrasound imaging, CT scan, Angiography, MRI), By Technology (Angiography, Angioplasty, Biopsy, Others), By Application (Cardiology, Gastroenterology, Oncology, Urology & Nephrology), By End-User (Hospitals, Ambulatory Surgical Centers, Others), and Geography- Global/Region/Country Forecast to 2028.” The global interventional radiology market size was valued at USD 18.2 billion in the year 2021 and anticipated to value at USD
Grass Pollen Allergy Treatment Market Growth Strategy, Import-Export Analysis An …
Precision Business Insights published a research report on “Grass Pollen Allergy Treatment Market: By Drug Class (Anti-histamines, Steroids, Beta-agonists, Immunotherapy Drugs), By Route of Administration (Oral, Parenteral, Inhalation), By Distribution Channel (Hospital Pharmacies, retail Pharmacies, Online Pharmacies), and Geography - Global/Region/Country Forecast to 2028". The global grass pollen allergy treatment market size was valued at 26,206.6 million in 2021 and is expected to reach 40,192.3 million by 2028, at a
Single Lead ECG Equipment Market Top Key Players Update And Forecast 2022
Precision Business Insights published a research report on “Global Single Lead ECG Equipment Market : By Product Type (Recording based Single lead ECG Equipment, Real time single lead ECG equipment), By Indication (Arrhythmia, Syncope and Others), By End User (Hospitals & Clinics, Homecare, ASCs), and Geography- Global/Region/Country Forecast to 2028”. The global single lead ECG equipment market anticipated to be valued at US$ XX Mn in the year 2021 and
Dental Consumables Market Latest Innovations, Drivers And Industry Status 2022 T …
Precision Business Insights published a research report on “Global Dental Consumables Market by Product (Dental Prosthetics, Dental Implants, Orthodontics, Periodontics, Retail Dental Care Essentials, Others), By Material (Metals, Ceramics, Polymers, Biomaterials, Others) and Geography- Global/Region/Country Forecast to 2028”. The global dental consumables market size is anticipated to grow at US $ 46.4 billion by 2028 and projected to grow at CAGR rate of 9.4% over the 2022-2028. Glance our

All 5 Releases

More Releases for Glioblastoma

Glioblastoma Multiforme Treatment Market : Global Glioblastoma Multiforme Treatm …
Glioblastoma Multiforme Treatment Market Precision Business Insights (PBI) in its report titled “Global Glioblastoma Multiforme Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2017 and Forecast 2018-2027” assesses the market performance over 2018-2027. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period. Glioblastoma multiforme is the high-grade glioma and
Global Glioblastoma Multiforme Therapeutics Market 2018 - Merck , Arbor Pharmace …
Accord Market, recently published a detailed market research study focused on the “Glioblastoma Multiforme Therapeutics Market” across the global, regional and country level. The report provides 360° analysis of “Glioblastoma Multiforme Therapeutics Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Glioblastoma Multiforme
Glioblastoma Multiforme Pipeline Review H1 2017
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2017, provides an overview of the Glioblastoma Multiforme (GBM) (Oncology) pipeline landscape. Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor. GBMs arise from glial cells, which are cells that form the tissue that surrounds and protects other nerve cells found within the brain and spinal cord. GBMs are mainly composed of star-shaped glial
Global Glioblastoma Multiforme Treatment Market sizes and predictions for growth
MarketResearchReports.Biz adds “Global Glioblastoma Multiforme Treatment Market Share, Size, Trends and Forecast Market Research Report” reports to its database. This report provides a strategic analysis of the Glioblastoma Multiforme Treatment and the growth estimates for the forecasted period. This report studies the global Glioblastoma Multiforme Treatment market, analyzes and researches the Glioblastoma Multiforme Treatment development status and forecast in United States, EU, Japan, China, India and Southeast Asia. Request Sample Copy of
Glioblastoma Multiforme Treatment (GBM) Industry Analysis by Segments
Glioblastoma multiforme (GBM) is a high-grade gliomas and the most malignant astrocytic tumor, composed of complexly differentiated neoplastic astrocytes, a subtype of central nervous system (CNS). Glioblastoma is clinically classified as grade IV astrocytoma and differs from anaplastic astrocytoma (grade III) due to the presence of necrotic tissue and hyperplastic blood vessels. The diagnosis of GBM is carried out with imaging modules such as computed tomography (CT), magnetic resonance imaging
Glioblastoma Treatment Drugs Market Expected to Dominate Worldwide by 2026
Brain tumors is one of the leading cause of cancer which is common among children and teenagers. Glioblastoma (GBM) is most common grade four tumor, is malignant and contains dead tumor cells. It is also called as Glioblastoma multiforme, it has variants of giant cell Glioblastoma and gliosarcoma found in cerebral hemisphere of brain. The exact cause of this tumor is not known but is also found in spinal cord